205 related articles for article (PubMed ID: 37896246)
21. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population.
Allabi AC; Gala JL; Horsmans Y
Pharmacogenet Genomics; 2005 Nov; 15(11):779-86. PubMed ID: 16220110
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the drug-drug interaction potential of treosulfan using a physiologically-based pharmacokinetic modelling approach.
Schaller S; Martins FS; Balazki P; Böhm S; Baumgart J; Hilger RA; Beelen DW; Hemmelmann C; Ring A
Br J Clin Pharmacol; 2022 Feb; 88(4):1722-1734. PubMed ID: 34519068
[TBL] [Abstract][Full Text] [Related]
23. How Informative Are Drug-Drug Interactions of Gene-Drug Interactions?
Lagishetty CV; Deng J; Lesko LJ; Rogers H; Pacanowski M; Schmidt S
J Clin Pharmacol; 2016 Oct; 56(10):1221-31. PubMed ID: 27040602
[TBL] [Abstract][Full Text] [Related]
24. Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug-Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors.
Chen G; Sun K; Michon I; Barter Z; Neuhoff S; Ghosh L; Ilic K; Song IH
J Clin Pharmacol; 2024 May; 64(5):590-600. PubMed ID: 38009271
[TBL] [Abstract][Full Text] [Related]
25. Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.
Watanabe A; Ishizuka T; Yamada M; Igawa Y; Shimizu T; Ishizuka H
Eur J Clin Pharmacol; 2022 Jan; 78(1):65-73. PubMed ID: 34415382
[TBL] [Abstract][Full Text] [Related]
26. Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug-Drug-Gene Interaction Predictions.
Loer HLH; Türk D; Gómez-Mantilla JD; Selzer D; Lehr T
Pharmaceutics; 2022 Apr; 14(5):. PubMed ID: 35631502
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator.
Wang K; Yao X; Zhang M; Liu D; Gao Y; Sahasranaman S; Ou YC
CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):441-454. PubMed ID: 33687157
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
29. Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug-Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 Phenotype.
Chiang M; Sychterz C; Perera V; Merali S; Palmisano M; Templeton IE; Gaohua L
Clin Pharmacol Ther; 2023 Oct; 114(4):922-932. PubMed ID: 37467157
[TBL] [Abstract][Full Text] [Related]
30. Tipifarnib physiologically-based pharmacokinetic modeling to assess drug-drug interaction, organ impairment, and biopharmaceutics in healthy subjects and cancer patients.
Okudaira N; Burt H; Mitra A
CPT Pharmacometrics Syst Pharmacol; 2024 May; ():. PubMed ID: 38807307
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the Potential for Drug-Drug Interactions with Inhaled Itraconazole Using Physiologically Based Pharmacokinetic Modelling, Based on Phase 1 Clinical Data.
Bergagnini-Kolev M; Kane K; Templeton IE; Curran AK
AAPS J; 2023 Jun; 25(4):62. PubMed ID: 37344751
[TBL] [Abstract][Full Text] [Related]
32. Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone.
Chen Y; Mao J; Hop CE
Drug Metab Dispos; 2015 Feb; 43(2):182-9. PubMed ID: 25324279
[TBL] [Abstract][Full Text] [Related]
33. Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.
Türk D; Hanke N; Wolf S; Frechen S; Eissing T; Wendl T; Schwab M; Lehr T
Clin Pharmacokinet; 2019 Dec; 58(12):1595-1607. PubMed ID: 31129789
[TBL] [Abstract][Full Text] [Related]
34. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
[TBL] [Abstract][Full Text] [Related]
35. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
Darwish M; Kirby M; Robertson P; Hellriegel ET
Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
[TBL] [Abstract][Full Text] [Related]
36. A comprehensive evaluation in clinic and physiologically-based pharmacokinetic modeling and simulation to confirm lack of cytochrome P450-mediated drug-drug interaction potential for pomotrelvir.
Yang Z; Rioux N; Vincent L; Jones HM; Cha D; Plummer A; Wilfret D; Kearney BP
CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1553-1564. PubMed ID: 37614073
[TBL] [Abstract][Full Text] [Related]
37. [Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy].
Yamamoto Y; Takahashi Y; Nishimura S; Ikumi Y; Mishima N; Kagawa Y
Yakugaku Zasshi; 2011; 131(5):809-15. PubMed ID: 21532277
[TBL] [Abstract][Full Text] [Related]
38. Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: Application to prospective simulation of complex drug-drug interaction with rivaroxaban.
Leow JWH; Ang XJ; Chan ECY
Br J Clin Pharmacol; 2023 Jun; 89(6):1873-1890. PubMed ID: 36683488
[TBL] [Abstract][Full Text] [Related]
39. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro-in vivo correlation with fluconazole.
Lu C; Berg C; Prakash SR; Lee FW; Balani SK
Drug Metab Dispos; 2008 Jul; 36(7):1261-6. PubMed ID: 18381488
[TBL] [Abstract][Full Text] [Related]
40. Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19.
Ke AB; Nallani SC; Zhao P; Rostami-Hodjegan A; Unadkat JD
Br J Clin Pharmacol; 2014 Mar; 77(3):554-70. PubMed ID: 23834474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
